Low Lung Cancer Incidence With Negative CT Prevalence Screen

This article originally appeared here.
Share this content:
Low Lung Cancer Incidence With Negative CT Prevalence Screen
Low Lung Cancer Incidence With Negative CT Prevalence Screen

TUESDAY, March 29, 2016 (HealthDay News) -- Participants with a negative low-dose computed tomography (CT) prevalence screen (T0) have lower incidence of lung cancer and lung cancer-specific mortality than all participants with a T0 screen, according to a study published online March 18 in The Lancet Oncology.

Edward F. Patz, Jr., M.D., from the Duke University Medical Center in Durham, N.C., and colleagues conducted a retrospective cohort analysis of data from the National Lung Screening Trial in high-risk eligible adults. The cohort included 26,231 participants assigned to the low-dose CT screening group who had undergone their T0 screen.

The researchers found that, compared with all 26,231 T0-screen participants, the 19,066 participants with a negative T0 screen had a lower incidence of lung cancer (371.88 versus 661.23 per 100,000 person-years) and had lower lung cancer-related mortality (185.82 versus 277.20 per 100,000 person-years). Among participants with a negative T0 screen, the yield of lung cancer at the first annual screen (T1) was 0.34 percent, compared with a yield of 1 percent at the T0 screen among all T0-screened participants. An additional 28 participants in the T0-negative group would have died from lung cancer over the course of the trial if the T1 screen had not been done in the T0-negative group.

"Because overly frequent screening has associated harms, increasing the interval between screens in participants with a negative low-dose CT prevalence screen might be warranted," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »